Swedish TIRmed Pharma raises 4,3m€ against atopic dermatitis

Stockholm-based biotech company TIRmed Pharma AB has announced the successful completion of a EUR 4.3 million funding round, led by Sciety and its investment network, Sciety Venture Partners. The capital will support the company’s progress toward clinical development of its novel treatment for atopic dermatitis, a chronic inflammatory skin disease that continues to present unmet therapeutic challenges.

The newly raised funds will be allocated to finalising toxicology studies, producing the drug under GMP conditions, and initiating a Phase Ib clinical trial in patients with atopic dermatitis.

Atopic dermatitis is among the most prevalent skin conditions globally, causing significant discomfort, including persistent itching, irritation, and disturbed sleep. While various treatment options are available, many patients experience limited long-term efficacy or adverse side effects, underlining the continued need for safer and more effective therapies.

TIRmed Pharma’s therapeutic candidate is a topically applied oligonucleotide designed to act locally at the site of inflammation. By modulating immune responses directly within the skin, the approach aims to deliver targeted treatment benefits while minimising systemic exposure and related side effects—a key limitation of many current therapies.

In preclinical evaluations, the treatment demonstrated encouraging outcomes, including long-lasting symptom relief extending up to 15 months after a short initial treatment course. The company’s goal is to provide a longer-acting and safer alternative to existing options, improving both patient outcomes and quality of life. “This investment marks a crucial milestone as we transition into clinical development,” said Leo Holmgren, CEO of TIRmed Pharma. “With the backing of Sciety and its network, we are well-positioned to accelerate our progress and bring new hope to patients living with atopic dermatitis.”

The financing round attracted notable investor interest, reflecting both the growing demand for innovation in dermatology and confidence in TIRmed Pharma’s clinical and strategic direction. “TIRmed Pharma is addressing a clear and pressing medical need,” noted Andreas Lindblom, Managing Partner at Sciety. “With solid preclinical data, a well-defined development plan, and a capable leadership team, the company aligns well with our investment focus.”

The global market for atopic dermatitis treatments is valued at around USD 9.3 billion, with expected annual growth of 8–10% through 2032, highlighting the market potential for new therapeutic solutions like TIRmed Pharma’s. Its lead candidate, TIR-C, is a topically applied oligonucleotide-based therapy targeting the underlying immune dysregulation in atopic dermatitis. With promising preclinical data and a strong scientific foundation, the company aims to redefine treatment standards in dermatological immunotherapy.